Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4647MR)

This product GTTS-WQ4647MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4647MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10406MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ6792MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ7651MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ151MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ4592MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ272MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ2245MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ7152MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW